SCHEMBL6574100

SCHEMBL6574100

CCCS(=O)(=O)NCCc1ccc2cc(OCCN)ccc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.44
KDM4E B2RXH2 1/20 0.44
TSHR P16473 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
SLC6A9 P48067 3/20 0.43
PTGS2 P35354 1/20 0.42
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
CA9 Q16790 3/20 0.40
CA14 Q9ULX7 3/20 0.40
CA12 O43570 2/20 0.40
CA5A P35218 2/20 0.40
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
CYP3A4 P08684 1/20 0.38
MTNR1A P48039 2/20 0.38
CA7 P43166 1/20 0.38
ITGB3 P05106 1/20 0.38
ITGA2B P08514 1/20 0.38
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6763747 0.87 ALDH1A1 (0.47) HSD17B10KDM4ETSHRSMN1; SMN2SLC6A9
SCHEMBL6571967 0.86 PTGS2 (0.45) SMN1; SMN2SLC6A9PTGS2CA1CA2
SCHEMBL6763718 0.86 KDM4E (0.46) HSD17B10KDM4ETSHRSMN1; SMN2SLC6A9
SCHEMBL6563319 0.84 SMN1; SMN2 (0.53) HSD17B10KDM4ETSHRSMN1; SMN2PTGS2
SCHEMBL6575368 0.83 PTGS2 (0.61) HSD17B10KDM4ETSHRSMN1; SMN2PTGS2
SCHEMBL6574096 0.83 GRIA4 (0.47) SMN1; SMN2PTGS2CA1CA2CA9
SCHEMBL6765791 0.82 PPARG (0.59) KDM4EALDH1A1HPGD
SCHEMBL6766142 0.80 LMNA (0.51) HSD17B10KDM4ETSHRSMN1; SMN2SLC6A9
SCHEMBL6573583 0.79 GRIA4 (0.48) HSD17B10KDM4ETSHRSLC6A9PTGS2
SCHEMBL6763704 0.77 ALDH1A1 (0.51) KDM4ESMN1; SMN2SLC6A9PTGS2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147612-A1 Sulfonamide derivatives DAVISON JOSHUA ZWICK (US) 2004-07-29 US disclosed
EP-1409452-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2004-04-21 EP disclosed
WO-2002098846-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147612-A1 Sulfonamide derivatives GRIN1, GRIN2A, GRIA1 HSD17B10 1260/4885KDM4E 3086/4885TSHR 614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.